Private Label Peptide Eye Patch Manufacturer Low MOQ

What are the labeling and regulatory requirements for peptide eye patches sold in the US and EU?

By Blake Mereby · Last reviewed October 12, 2026

Peptide eye patches sold as cosmetics (not drugs) in the US and EU are regulated as cosmetic products, which means they must comply with labeling, ingredient listing, and safety substantiation rules in each market. The requirements differ enough that you should plan for each market separately rather than assuming a US-compliant label is automatically EU-compliant.

In the United States, FDA 21 CFR Part 701 governs cosmetic labeling. Required elements include: product identity statement (e.g., 'Hydrogel Eye Patches'), net quantity of contents, name and address of the responsible party (distributor or manufacturer), ingredient list in descending order of predominance using INCI nomenclature, and any required warnings (for example, 'Keep out of reach of children' or 'For external use only'). Under MoCRA (enacted December 2022), cosmetic facilities must register with the FDA and list their products — a process rolling out through 2024–2025. Serious adverse event reporting is also now mandatory.

In the European Union, EC No 1223/2009 applies. Required label elements include: a responsible person established in the EU (post-Brexit, this cannot be a UK entity), country of origin if outside the EU, batch number, period-after-opening symbol (e.g., '12M' for 12 months), function of the product, precautions, and a full INCI ingredient list. The EU also requires a Product Information File (PIF) maintained by the responsible person, containing the product description, cosmetic product safety report (CPSR) signed by a qualified safety assessor, manufacturing method, GMP compliance evidence, and evidence of the claimed effect. The CPSR is the document that most indie founders underestimate — it's not a quick form, it's a full toxicological evaluation that typically costs $800–$2,500.

For both markets, any claim that implies a drug action — 'reduces wrinkles by 47%,' 'clinically proven to regenerate skin cells' — moves the product from the cosmetic regulatory lane into the drug/quasi-drug lane with significantly higher regulatory burden. Stick to cosmetic claims: 'visibly reduces the appearance of fine lines,' 'skin looks more hydrated and firmer.'

Korea (KFDA), Canada (Health Canada), and Australia (TGA) each have their own requirements if you plan to expand there. Korean KFDA registration can take 6–12 months; Canadian Cosmetic Notification is faster (30-day notification before first import).

The most common labeling mistake is using non-INCI ingredient names (e.g., 'Argireline' is a trade name — the correct INCI is 'Acetyl Hexapeptide-3') or listing ingredients in the wrong order. Your manufacturer's cosmetic chemist should provide a regulatory-ready INCI list, but always have it independently reviewed by a US or EU regulatory consultant before printing packaging.

AJ Cosmo Labs connects founders with both manufacturers and regulatory consultants, so you can coordinate formula documentation and compliance review in the same workflow rather than managing them as separate vendor relationships.

Ingredients in this answer: Argireline

Read the full guide on Private Label Peptide Eye Patch Manufacturer Low MOQ →

More about Private Label Peptide Eye Patch Manufacturer Low MOQ

Tell us about your product

Tell us what you're selling and where. You can hire a vetted cosmetic chemist on AJ Cosmo Labs to review your formula and labeling. Starting is free.

Free to start · no credit card · continue in your browser or the iPhone app.

Have a product idea?

Connect with vetted cosmetic chemists and custom labs on AJ Cosmo Labs.

Get on the App Store Open the web app